D. Pankov

发表

T cell receptor mimic antibodies for cancer therapy

D. Scheinberg, Aaron Y. Chang, Ron S. Gejman, 2016, Oncoimmunology.

CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.

W. Sellers, N. Socci, A. Viale, 2015, Cancer cell.

Therapeutic Efficacy of an Fc-Enhanced TCR-like Antibody to the Intracellular WT1 Oncoprotein

Sun-Mi Park, D. Scheinberg, C. Liu, 2014, Clinical Cancer Research.

Cancer Therapy: Preclinical TherapeuticEfficacyof anFc-EnhancedTCR-likeAntibody to the Intracellular WT1 Oncoprotein

Sun-Mi Park, D. Scheinberg, M. Kharas, 2014 .

TherapeuticEfficacyofanFc-EnhancedTCR-likeAntibodyto the Intracellular WT1 Oncoprotein

Sun-Mi Park, D. Scheinberg, M. Kharas, 2014 .

Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to viral directed immunotherapy.

O. Elemento, E. Cesarman, J. Phillip, 2020, Blood.

PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates

S. Larson, H. Scher, R. Damoiseaux, 2020, Clinical Cancer Research.

Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2

D. Pankov, N. Cheung, S. S. Hoseini, 2017, Oncoimmunology.

Mechanisms of leukemia resistance to antibody dependent cellular cytotoxicity

D. Scheinberg, E. Casey, T. Dao, 2016, Oncoimmunology.

In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME)

S. Larson, M. McDevitt, D. Veach, 2017, Oncotarget.

LYMPHOID NEOPLASIA A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL 1 leukemias

D. Scheinberg, A. Scott, T. Dao, 2014 .

leukemias + resistance in human BCR-ABL A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor

D. Scheinberg, T. Dao, L. Dubrovsky, 2014 .

resistance in human BCR-ABL A TCR-mimic antibody to WT 1 bypasses tyrosine kinase inhibitor

D. Scheinberg, A. Scott, T. Dao, 2014 .

Targeting the Intracellular WT1 Oncogene Product with a Therapeutic Human Antibody

D. Scheinberg, P. Maslak, M. Curcio, 2013, Science Translational Medicine.

Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias.

D. Pankov, R. O'reilly, E. Doubrovina, 2012, Blood.

A small-molecule c-Rel inhibitor reduces alloactivation of T cells without compromising antitumor activity.

G. Altan-Bonnet, M. V. D. van den Brink, C. Lezcano, 2014, Cancer discovery.

Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1

D. Scheinberg, V. Ponomarev, C. Liu, 2015, Nature Biotechnology.

Opportunities and challenges for TCR mimic antibodies in cancer therapy

D. Scheinberg, Aaron Y. Chang, Ron S. Gejman, 2016, Expert opinion on biological therapy.

TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies.

N. Cheung, Mahiuddin Ahmed, D. Pankov, 2018, JCI insight.

CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.

W. Sellers, N. Socci, A. Viale, 2015, Cancer cell.

Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias.

D. Pankov, R. O'reilly, E. Doubrovina, 2012, Blood.

NY-ESO-1 and LAGE1A: An emerging target for cell therapies in solid tumours

K. Auger, J. Euesden, C. Britten, 2019, Annals of Oncology.

A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias.

D. Scheinberg, T. Dao, L. Dubrovsky, 2014, Blood.

LYMPHOID NEOPLASIA A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL 1 leukemias

D. Scheinberg, T. Dao, L. Dubrovsky, 2014 .